Quantcast

Latest Biomarker Stories

2014-06-04 12:28:56

TUCSON, Ariz., June 4, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group and MedImmune, the global biologics research and development arm of AstraZeneca, today announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only...

2014-06-04 04:21:45

VIENNA, June 4, 2014 /PRNewswire/ -- AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients. Upon treatment with AD04, effects consistent with disease modification were achieved for at least 18 months in 47% of treated patients. This beneficial effect was dose dependent and more effective in...

2014-06-03 08:32:14

NEW YORK, June 3, 2014 /PRNewswire/ -- Exosome Diagnostics, a leading developer of non-invasive, biofluid-based molecular diagnostics, today announced that Vincent J. O'Neill, M.D., has been appointed as its chief medical officer. Dr. O'Neill has extensive experience in clinical trial design, regulatory issues, and personalized medicine, most recently as global head Personalized of Medicine and Companion Diagnostics at Sanofi. At Sanofi, he defined the personalized medicine...

2014-06-03 08:27:57

LONDON, June 3, 2014 Reportbuyer.com has added a new market research report:Aptamers Market - Technology Trend Analysis By Applications - Therapeutics, Diagnostics, Biosensors, Drug Discovery, Biomarker Discovery, Research Applications with Market Landscape Analysis - Global Forecasts to...

2014-06-01 08:20:22

Large International Cohort of 17 GI Cancer Types Confirms the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, June 1, 2014 /PRNewswire/ -- Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data at the 50th Annual Meeting of ASCO in which molecular profiling identified numerous potential drug options in patients with various types of gastrointestinal (GI) cancer. Among...

2014-05-31 08:21:15

New DecisionDx-EC multi-analyte test data presented at ASCO 2014 CHICAGO, May 31, 2014 /PRNewswire/ -- Castle Biosciences Inc. today announced study results from its proprietary multi-analyte test DecisionDx-EC, which is designed to determine which patients with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy. The results were reviewed in a poster presentation at the 50(th) Annual Meeting of the American Society of Clinical...

2014-05-31 08:20:38

Clinical Studies in Gynecologic Cancers Confirm the Unique Clinical Utility of Caris Molecular Intelligence(TM) CHICAGO, May 31, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data from studies demonstrating the potential utility of comprehensive molecular profiling in guiding treatment of patients with gynecologic malignancies, including breast cancers and ovarian...

2014-05-30 16:25:06

John Lillig to Lead Agena Bioscience as Chairman and Interim CEO SAN DIEGO, May 30, 2014 /PRNewswire/ -- Agena Bioscience, Inc., a portfolio company of Telegraph Hill Partners (THP), today acquired the Bioscience business of Sequenom, Inc. (NASDAQ: SQNM), which sells the MassARRAY® System for mass spectrometry-based detection of nucleic acids in research and clinical laboratories. Agena Bioscience has retained the employees of the acquired segment and will remain headquartered in...

2014-05-30 08:24:40

Role Further Enhances Company's Medical Leadership Capabilities IRVING, Texas, May 30, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today that it has named Sandeep K. Reddy, M.D., as its Chief Medical Officer. Dr. Reddy most recently served as Senior Medical Director for Caris before assuming the Chief Medical Officer role. In his new capacity, Dr. Reddy will lead the company's research...

2014-05-30 04:22:13

HILDEN, Germany, and GERMANTOWN, Maryland, May 30, 2014 /PRNewswire/ -- - Fourth oncology project with Lilly expands QIAGEN's Personalized Healthcare pipeline - Development of modular assay panels focuses on multiple biomarkers targeting cellular pathways associated with innovative cancer therapies under development by Lilly - Project to include assays for QIAGEN's new multi-modal, multi-analyte Modaplex...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related